Challenges in optimizing the treatment of Pneumocystis pneumonia in the intensive care unit
Intensive Care Med
.
2024 Oct;50(10):1719-1720.
doi: 10.1007/s00134-024-07568-4.
Epub 2024 Aug 5.
Authors
Florian Reizine
1
,
Nahema Issa
2
,
Romain Lécuyer
3
4
,
Benoit Tessoulin
5
,
Benjamin Gaborit
6
7
Affiliations
1
Service de Réanimation Polyvalente, Centre Hospitalier de Vannes, Vannes, France. florian.reizine@gmail.com.
2
Internal Medicine and Infectious Disease Unit, Groupe Saint-André, University Hospital, Bordeaux, France.
3
Infectious Diseases, Centre Hospitalier de Cholet, Cholet, France.
4
UR 1155, Laboratory of Targets and Drugs for Infections and Cancer, IRS2-Nantes Biotech, Nantes, France.
5
Hematology Department, Nantes University Hospital, INSERM U1232, CRCI2NA, Nantes University, Nantes, France.
6
Department of Infectious Diseases, University Hospital of Nantes and Centre d'Investigation Clinique 1413, INSERM, Nantes, France.
7
EA 3826, Laboratory of Clinical and Experimental Therapeutics of Infections, IRS2-Nantes Biotech, Nantes, France.
PMID:
39102026
DOI:
10.1007/s00134-024-07568-4
No abstract available
Publication types
Letter
MeSH terms
Antifungal Agents / therapeutic use
Humans
Intensive Care Units* / organization & administration
Pneumocystis carinii
Pneumonia, Pneumocystis* / drug therapy
Substances
Antifungal Agents